Hansa Biopharma
29.12 SEK
-2.61 %
Less than 1K followers
HNSA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Hansa Biopharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 3.4 | 6.1 | 33.9 | 154.5 | 134.1 | 171.3 | 222.3 |
| growth-% | 81.3 % | 455.6 % | 356.1 % | -13.2 % | 27.8 % | 29.7 % | |
| EBITDA | -359.7 | -422.8 | -547.0 | -587.1 | -788.5 | -637.4 | -520.7 |
| EBIT | -359.7 | -422.8 | -547.0 | -587.1 | -788.5 | -637.4 | -520.7 |
| Profit before taxes | -359.6 | -420.9 | -548.1 | -608.4 | -830.8 | -803.7 | -527.0 |
| Net income | -360.0 | -420.9 | -548.3 | -609.6 | -831.7 | -806.7 | -529.3 |
| EPS | -8.99 | -10.16 | -12.33 | -13.57 | -15.83 | -12.84 | -6.52 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -10,691.7 % | -6,933.5 % | -1,614.5 % | -379.9 % | -588.0 % | -372.0 % | -234.3 % |
| EBIT-% | -10,691.7 % | -6,933.5 % | -1,614.5 % | -379.9 % | -588.0 % | -372.0 % | -234.3 % |
| ROE | -64.0 % | -33.9 % | -72.4 % | -100.6 % | 495.4 % | 136.9 % | 629.1 % |
| ROI | -54.2 % | -29.3 % | -54.1 % | -36.1 % | -81.7 % | -100.8 % | -45.4 % |